Payer Documentation Asks
What each major payer typically wants on file for oncology infusion and specialty oncology drug authorizations. Pre-call checklist captured from payer medical policies, NCCN Compendia, and ASCO/ASH guideline recommendations.
| Documentation Ask | Why the payer wants it | Anchor source |
|---|---|---|
| NCCN Compendia citation | Confirms the requested regimen / drug is designated Category 1 or 2A for the indication, satisfying payer medical-policy evidence thresholds. | NCCN Compendia — current indication-specific category and "Use" listing for the requested regimen. |
| Line of therapy | Payers restrict coverage based on first-line vs. subsequent-line use; medical policy is line-of-therapy specific. | Stage, prior treatment history, and current regimen number documented in the oncologist's note; NCCN-defined algorithm position. |
| Prior systemic therapy trial | Step-therapy policies require documented trial-and-failure of preferred / formulary agents before the requested regimen. | Drug-by-drug, dose-by-dose trial history with dates of discontinuation and documented reason (progression, intolerance, contraindication). |
| ECOG / Karnofsky performance status | Functional capacity gates fitness for the requested regimen and is required per many payer infusion policies. | Most recent ECOG (0–4) or Karnofsky (0–100) score on file within the visit window for the regimen decision. |
| Biomarker / mutation result | Targeted therapy approvals are indication-tied to a specific biomarker or mutation result (e.g. EGFR, ALK, HER2, PD-L1, BRCA, MSI). | Pathology report, NGS or IHC result, FDA prescribing information companion-diagnostic requirement. |
| Biosimilar step / preference | Many payers mandate a formulary-preferred biosimilar (filgrastim, pegfilgrastim, rituximab, trastuzumab) before the reference product. | Payer formulary, FDA biosimilar licensing status, documented contraindication or prior intolerance to the preferred biosimilar. |
| Lab / imaging markers | Lab values (CBC, CMP, ANC, hepatic, renal) and imaging (RECIST 1.1 progression, stage) anchor the regimen's appropriateness at this visit. | Most recent labs within visit window; imaging report with comparison; RECIST classification where applicable. |
| Pregnancy / contraception attestation | Many oncology regimens carry teratogenic risk; payers require documented contraception counseling and pregnancy testing where applicable. | iPLEDGE / REMS program attestation (where applicable); contraception counseling note; negative pregnancy test within visit window. |
Common Denial Reasons + Counter-Arguments
The denial reasons most often returned for tier-2 oncology / infusion authorizations and the directional counter-arguments our team builds around documented patient evidence.
| Denial reason | Payer rationale | Counter-direction |
|---|---|---|
| Off-label / compendia not cited | "Requested use is off-label; payer medical policy does not list the indication." | Anchor Risk + Timeline: cite NCCN Compendia Category 1 / 2A, ASCO/ASH guideline recommendation, FDA prescribing information for the indication, and the absence of on-label alternatives for this patient's clinical context. |
| Step therapy / preferred biosimilar not tried | "Patient must fail preferred formulary agents (including biosimilars where available) before the requested drug is approved." | Anchor Monitoring: confirmed drug-by-drug, dose-by-dose trial history — including the payer's preferred biosimilar — with dates of discontinuation and documented reason. FDA label and society guidelines may carve out cases where step therapy is inappropriate. |
| Insufficient biomarker documentation | "Companion-diagnostic biomarker not documented; medical necessity cannot be established for the requested targeted therapy." | Anchor Anatomy + Risk: pathology / NGS / IHC result on file with the specific mutation or expression-level threshold the FDA label / NCCN recommendation requires for the requested agent. |
| Line of therapy not supported | "Requested regimen is not supported at this line of therapy per payer medical policy." | Anchor Timeline + Monitoring: documented treatment course to date, prior regimen response, RECIST / progression assessment, and the regimen's NCCN-defined algorithm position for this line. |
| Performance status not documented | "ECOG / Karnofsky score on file does not support fitness for the requested regimen." | Anchor Symptom + Risk: most recent ECOG or Karnofsky on file within the visit window, with documented functional status supporting the regimen choice per FDA prescribing information. |
| Site-of-service mismatch | "In-office or outpatient infusion setting is appropriate; hospital-based infusion is not medically necessary." | Anchor Anatomy + Risk: clinical factors that require hospital-level staffing, monitoring, or rescue capability (anaphylaxis / hypersensitivity protocol, hemodynamic monitoring requirements, infusion reaction history, central-line access needs). |
| Frequency / dose exceeds policy | "Requested interval or dose is more frequent / higher than the payer policy limit." | Anchor Timeline + Monitoring: documented disease activity (RECIST, lab / imaging markers) that justifies the intensification. Cite FDA label dosing and society guideline escalation criteria. |
| Supportive agent not separately covered | "Pegfilgrastim / denosumab / antiemetic requested is bundled into the primary chemotherapy regimen." | Anchor Risk + Symptom: documented neutropenia risk, bone-metastasis disease burden, or documented emetogenicity tier per NCCN antiemesis guideline that supports the supportive agent as separately billable and medically necessary. |
SMART Clinical Factors That Move the Needle
Per indication, the SMART anchors our team confirms are documented pre-submission. The SMART framework is VCS's own scoring rubric; clinical thresholds are anchored to NCCN Compendia, ASCO/ASH guidelines, and FDA prescribing information.
Chemotherapy Infusion (J9640–J9999)
Pre-call check: confirm the diagnosis, stage, line of therapy, NCCN Compendia citation, ECOG / Karnofsky, and the lab / imaging markers anchoring the regimen choice at this visit.
S
Symptom
Symptom burden (pain, performance status change), disease-related symptoms, prior-cycle tolerance.
M
Monitoring
Lab markers within visit window (CBC, CMP, ANC, hepatic, renal), RECIST 1.1 classification on imaging comparison.
A
Anatomy
Stage and primary / metastatic sites, biopsy- or resection-confirmed histology where applicable.
R
Risk
ECOG / Karnofsky, prior-cycle toxicity profile, REMS attestation where applicable.
T
Timeline
Line of therapy, prior regimens with dates and outcomes, intended cycle number.
Source: NCCN Compendia (category-specific designation for the indication and line); FDA prescribing information for each agent in the regimen.
Supportive Agents — Pegfilgrastim, Denosumab, Antiemetics
Pre-call check: confirm the primary chemotherapy regimen, neutropenia or bone-metastasis risk, NCCN antiemesis guideline emetogenicity tier, and the formulary-preferred biosimilar where applicable.
S
Symptom
Febrile-neutropenia history, bone-pain burden, chemotherapy-induced nausea / vomiting severity on prior cycles.
M
Monitoring
ANC nadirs on prior cycles, calcium and vitamin D for denosumab, prior-cycle antiemetic response.
A
Anatomy
Bone-metastasis burden for denosumab, disease distribution informing SRE risk profile.
R
Risk
FN risk per regimen, prior intolerance to the payer's preferred biosimilar where relevant, hypocalcemia or osteonecrosis risk for denosumab.
T
Timeline
Schedule relative to chemotherapy (e.g. 24hrs post-cycle for pegfilgrastim), duration on therapy, prior supportive-agent exposure.
Source: NCCN antiemesis guideline (emetogenicity tier); FDA prescribing information for pegfilgrastim, denosumab, and formulary biosimilars.
Rituximab — Oncology & Hematology
Pre-call check: confirm the hematologic / oncologic indication, prior-therapy trial history, and the payer's preferred rituximab biosimilar where on formulary.
S
Symptom
Indication-specific severity (e.g. IPSS for MDS, disease activity for lymphoma subtypes, RA disease-activity scores).
M
Monitoring
Lab markers (CBC, disease-specific biomarkers), prior imaging, hepatitis B / C screening per FDA label.
A
Anatomy
Disease distribution and organ involvement relevant to the requested rituximab indication.
R
Risk
Infusion-site complexity, hypersensitivity protocol, infection-risk screening (hepatitis B reactivation) per FDA label.
T
Timeline
Induction vs. maintenance schedule, prior rituximab exposure and outcomes, prior biosimilar trial where applicable.
Source: FDA prescribing information for rituximab (Rituxan) and the FDA-approved biosimilars; NCCN Compendia indication-specific category.
Trastuzumab — HER2+ Oncology
Pre-call check: confirm HER2 IHC / ISH result at the FDA-label-defined threshold, the line of therapy, prior anti-HER2 trial history, and the payer's preferred trastuzumab biosimilar.
S
Symptom
Disease-related symptom burden, metastatic vs. adjuvant context, prior-cycle tolerance.
M
Monitoring
HER2 IHC score (0/1+/2+/3+) and ISH amplification ratio, LVEF on serial echo per FDA label, imaging response.
A
Anatomy
Stage, hormone-receptor co-expression, sites of metastatic disease where relevant.
R
Risk
Cardiotoxicity monitoring (LVEF threshold per FDA label), prior intolerance to the payer's preferred biosimilar.
T
Timeline
Adjuvant cycle number, metastatic line of therapy, prior anti-HER2 exposure (including biosimilar) and outcomes.
Source: FDA prescribing information for trastuzumab (Herceptin) and FDA-approved biosimilars; NCCN Compendia HER2+ indication-specific category; ASCO HER2 testing guideline.
Pembrolizumab — PD-1 Inhibitor
Pre-call check: confirm the FDA-label indication, the companion-diagnostic PD-L1 IHC or MSI / dMMR result, prior systemic-therapy trial history, and immune-related adverse-event screening.
S
Symptom
Disease-related symptom burden, performance status, prior-line progression assessment.
M
Monitoring
PD-L1 IHC (TPS / CPS per FDA label companion-diagnostic), MSI / dMMR result where indicated, RECIST 1.1 progression.
A
Anatomy
Stage and primary / metastatic distribution; site-specific disease burden.
R
Risk
irAE screening (autoimmune history, organ-function baseline), steroid taper plan per FDA label.
T
Timeline
Line of therapy, prior PD-1 / PD-L1 exposure, prior systemic regimens with response and progression dates.
Source: FDA prescribing information for pembrolizumab (Keytruda) and the companion-diagnostic PMA for the indicated PD-L1 assay; NCCN Compendia indication-specific category.
Example Framing — Q&A
Adapt to your patient's documented evidence; do not introduce new clinical claims live.
"Why this regimen rather than the formulary-preferred biosimilar step?"
Patient has documented trial-and-failure of the preferred biosimilar (drug, dose, duration, reason for discontinuation). Severity and current disease activity meet the criteria in NCCN Compendia and the FDA prescribing information for the requested agent. Step-therapy substitution is no longer clinically appropriate at this line.
"Why HER2 IHC re-stain or repeat biopsy before reauthorization?"
Current HER2 status is anchored to the most recent pathology report on file; the ASCO HER2 testing guideline supports the assay used and the threshold (IHC 3+ or ISH-amplified) the FDA label requires for the requested agent.
"Why hospital-based infusion rather than outpatient?"
Patient has documented clinical factors that warrant hospital-level monitoring or rescue capability during the infusion: prior hypersensitivity reaction history, hemodynamic monitoring requirements, or central-line access needs per the requesting department's protocol.
Paired With Your Live Denial Intelligence
This playbook is editorial — for real-time win rates by payer and denial reason, use the live dashboards.
Live data
Denial Defense Analytics
Payer × denial-reason patterns, SMART clinical factors correlated with successful appeals, and ranked denial reasons from VCS-supported cases.
Open the live dashboard →
CPT intelligence
CPT Denial Defense Library
CPT-code-level defense patterns, required documentation, payer-specific criteria, and ready-to-use appeal templates.
Open the Defense Library →